Botanix Pharmaceuticals Preliminary Final Report

Key highlights

·        Successfully completed the BTX 1530 Phase 1b acne patient and advanced into Phase 2 clinical development in June 2108

·        Successfully completed the BTX 1204 Phase 1b atopic dermatitis patient study, with preparations well advanced to move into Phase 2 clinical development in the near term

·        Completed pre-clinical work and testing for BTX 1303 (Psoriasis) and announced development of new product BTX 1801 (Antimicrobial) with both products rapidly advancing into the next stage of clinical development

·        Fully funded to complete Phase 2 clinical trials for BTX 1503 and BTX 1204 as well as to progress pipeline products

·        Subsequently to year end, Botanix was awarded the Innovation Connections Grant and appointed Dr. Stephane Levy as Chief Medical Officer and Ms Jillian Chapas-Reed as Senior Director of Clinical Operations

Philadelphia PA and Sydney Australia, 31 August 2018 -- Medical dermatology company Botanix Pharmaceuticals Limited (ASX:BOT, “Botanix” or the “Company”) is pleased to release its preliminary final report for the year ending 30 June 2018.

To read the ASX announcement, please click here

Have you seen our earlier videos?

Click here to visit our new YouTube page

Click here to watch an introduction to Botanix Pharmaceuticals

Click here to watch the BTX 1204 Presentation

Click here to watch an interview with CMO, Dr Stephane Levy

For more information, please visit www.botanixpharma.com or follow us on Twitter @BotanixPharma

General Enquiries
Matt Callahan
Botanix Pharmaceuticals
Executive Director
P: +1 215 767 4184
E: mcallahan@botanixpharma.com

Investor Enquiries
Joel Seah
Vesparum Capital
P: +61 3 8582 4800
E: botanixpharma@vesparum.com

Media Enquiries
Julia Maguire
The Capital Network
P: +61 419 815 386
E: julia@thecapitalnetwork.com.au